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In general the evaluation of these medicines is limited to the identiﬁcation and the dosage of the active
ingredients. In this study in vitro dissolution tests were conducted on two sets of counterfeit medicines
containing PDE-5 inhibitors (sildenaﬁl citrate and tadalaﬁl). The dissolution proﬁles were statistically
compared to the ones of the genuine products using the f2-method and a comparison at each time point
using the Cochran test.
The results showed low equivalences between counterfeit and genuine products as well as higher
variations around the mean dissolution value at the different time points for the counterfeit products.
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Nowadays it is estimated that about 10–15% of the medicine
market worldwide is covered by counterfeit products. However,
the highest precedence of counterfeit medicines can be found in
developing countries with a weak regulatory system, where it is
estimated that about 30% of the medicines on sale are counter-
feited. In some countries this percentage can even be as high assity. Production and hosting by Else
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n Jiaotong University.60% of the medicines on sale. In industrialised countries the
problem is less severe with less than 1% of the medicine market
affected [1–3]. Between industrialised and developing countries,
differences also exist in the type of counterfeit medicines
encountered. In developing countries life-saving medicines, like
antibiotics, anti-malaria products, HIV-inhibitors, etc. are often
counterfeited [4–7], while in industrialised countries they are
mainly life-style drugs like PDE-5 inhibitors and anorexics [8].
However, it should be mentioned that counterfeited antineoplastic
and cardiovascular drugs were also detected in the western
world [9].
The treatment of diseases with high untreated mortality rates
such as malaria, pneumonia, meningitis, and AIDS with counter-
feit medicines will lead to not only an increase of mortality and
morbidity, but also an increasing risk of developing microbial
resistance. The latter is due to the fact that counterfeit medicinesvier B.V. All rights reserved.
Dissolution of counterfeit medicines 251often contain active ingredients in sub-therapeutic dosages. In this
case, even genuine medicines can become inefﬁcient [10]. For
counterfeited life-style drugs, the risks are more situated in the
presence of toxic impurities or components, unexpected active
ingredients or unauthorized and untested analogues or designer
molecules, a wrong dosage, exceeding the maximum daily intake
and wrong, missing or inadequate information concerning the use
of the drug [8].
WHO [11] deﬁnes the counterfeit drug as: “one which is
deliberately and fraudulently mislabelled with respect to identity
and/or source. Counterfeiting can apply to both branded and
generic products and counterfeit products may include products
with the correct ingredients or with the wrong ingredients, without
the active ingredients, with insufﬁcient active ingredient or with
fake packaging.” Next to this deﬁnition WHO also deﬁnes the
substandard medicine (also called out of speciﬁcation (OOS)
products) as “a genuine medicine produced by manufacturers
authorized by the National Medical Regulatory Authority which
do not meet the quality speciﬁcations set for them by national
standards.” By deﬁnition, the latter group of medicines should not
be present in the market. If they are, a problem has occurred with
the control of the legitimate supply chain or there have been
unscrupulous activities and reselling of those medicines that
should have been destroyed [10].
In literature numerous papers can be found in which several
analytical techniques are used for detection and characterisation of
counterfeit medicines [1]. These papers, however, limit themselves
to the detection of counterfeits, the identiﬁcation of the active
ingredients, the dosage of these active components, and in some
cases the presence of impurities. Though the effectiveness, the
toxicity and the risks for public health can also be inﬂuenced by
other parameters, it should be kept in mind that most of the
counterfeit medicinal products on the market are manufactured
without taking into account the principles of good manufacturing
procedures and that they are sold without any kind of quality
control. This may lead to the fact that even if products are found
with the correct active ingredient and in the correct dose, the
quality of the ﬁnished product can inﬂuence the effectiveness/
secondary effects of the product. These inﬂuences can be due to
the type or nature of the used excipients, which can differ from the
ones of the genuine products, to the production process like the
pressure used to compress the tablets, and to the storage and
transport conditions of the ﬁnished products.
Only a limited number of papers have already addressed this
issue by performing in vitro dissolution tests with genuine, generic
and counterfeit medicines. Most of these studies were conducted
for anti-malarial products on the market in developing countries
[4,12–14]. Gaudiano et al. [4] performed a quality analysis of
counterfeit and substandard anti-malarials on the informal market
in Congo, Burundi and Angola. They found that about 50% of the
samples showed sub-standard technological properties and very
low dissolution proﬁles, which could affect bioavailability and
bioequivalence in comparison with branded products [4].
In this paper a dissolution study for counterfeit and imitation
samples, containing PDE-5 inhibitors, was performed by using
in vitro dissolution testing. Genuine, counterfeit and imitation
samples of Viagras and Cialiss were analysed in order to obtain
dissolution proﬁles. These proﬁles were statistically compared.
To our knowledge it is the ﬁrst time such a study is conducted on
counterfeit products found on the European market. As a
consequence the knowledge about the dissolution proﬁles of
counterfeit products is important in the risk assessment of theseproducts. This risk assessment can both be used to focus custom
campaigns on the most dangerous products and otherwise to
sensitise the public for the problem based on the scientiﬁc data, in
order to lower the demand for these counterfeit products.2. Materials and methods
2.1. Samples
All counterfeit and imitation samples were donated by the Federal
Agency for Medicines and Healthcare Products (FAMHP) in
Belgium. Genuine samples of Viagras were kindly provided by
Pﬁzer SA/NV (Puurs, Belgium). Eli Lilly SA/NV (Benelux) kindly
provided genuine samples of Cialiss.
2.2. Chemicals and reagents
The reference standards for sildenaﬁl citrate and tadalaﬁl were
kindly donated by Pﬁzer SA/NV (Puurs, Belgium) and Eli Lilly
SA/NV (Benelux), respectively.
Acetonitrile HPLC grade was purchased from Biosolve (Valk-
enswaard, the Netherlands). Formic acid 99% and sodium dodecyl
sulphate were purchased from VWR international (Leuven, Bel-
gium). Ammonia solution 25% (m/m) and chloric acid 36% (m/m)
were purchased from Merck (Darmstadt, Germany).
2.3. Instrumental conditions
2.3.1. Dissolution
The dissolution tests were performed using a Sotax AT6 and a
Sotax AT7 Smart dissolution device (Sotax, Alschwil, Switzer-
land). The dissolutions were performed following test device 2
(paddle) as described by the European Pharmacopoeia [15]. The
rotation speed was set at 50 rpm and the vessels temperature at
37.070.5 1C. For the sildenaﬁl-containing samples 1 L of 0.5%
sodium dodecyl sulphate (SDS) was used as dissolution medium,
while 900 mL of 0.01 M HCl was used for the tadalaﬁl-containing
samples.
Two millilitres of dissolution medium were sampled at 5, 10,
15, 30, 45, 60 and 120 min, respectively, after starting the test. The
amount of dissolution medium sampled was not replaced. The loss
of medium was corrected during calculation of the dissolution
proﬁle [16]. Due to the limited amount of sample available, all the
samples were only tested in triplicate.
Tablets and gels were just added to the dissolution medium at
the start of the dissolution tests. Capsules and soft caps were
positioned in a metallic scaffold, especially designed for dissolu-
tion tests with apparatus 2, and added to the dissolution medium at
the start of the tests.
2.3.2. HPLC
The quantiﬁcations in both samples and dissolution media were
performed on a Waters 2695 Alliances chromatographic system
(Waters Corporation, Milford, USA). The system consisted of a
quaternary pump, a temperature controlled autosampler and a
column heater, coupled to a Waterss 2998 Diode Array Detector
(DAD). The output signal was monitored and processed using the
Waters Empowers2 software. The analysis was performed on a
Waters XTerra RP18 (150 mm 4.6 mm, 5 mm) chromatographic
column using a gradient with a 10 mM ammonium formate buffer
E. Deconinck et al.252pH 3.5 as aqueous phase and acetonitrile as organic modiﬁer. The
gradient started at 70% buffer. The gradient reached 65% buffer in
5 min and went further down to 55% in 3 min. Afterwards a
plateau of 20% buffer reached in one minute and held for two
minutes before returning to the initial conditions. The ﬂow was
1 mL/min; the column temperature was set at 30 1C; the sample
temperature was set at 15 1C and detection was performed at a
wavelength of 254 nm. For the samples containing sildenaﬁl
citrate the injection volume was set at 5 mL, while for the
tadalaﬁl-containing samples it was set at 20 mL [17].2.4. Preparation of standards and samples
Stock solutions of sildenaﬁl citrate and tadalaﬁl of 1.0 mg/mL and
0.2 mg/mL, respectively, were prepared using acetonitrile/water
(50/50) as solvent.
Calibration standards of 25, 50, 100 and 150 mg/mL for
sildenaﬁl citrate were prepared by dilution of the stock solution
with acetonitrile/water (50/50). Tadalaﬁl calibration standards of 5,
10, 20 and 40 mg/mL were prepared using the same procedure.
Before dissolution the dosage of sildenaﬁl citrate and tadalaﬁl in
each of the samples was assayed. This was done on one dosage
unit, due to the limited amount of sample at our disposal. The
dosage unit was brought into 100 mL of acetonitrile/water 50/50
and stirred for at least 30 min. The obtained solutions were then
diluted 10 times with the same solvent and ﬁltered through a
0.2 mm polytetraﬂuoroethylene syringe ﬁlter (∅ 13 mm, VWR
international). Each sample solution was injected twice. Concen-
trations were back calculated using the calibration lines obtained
with the prepared standards and calculated using least-squares
regression.2.5. Calculations
All calculations were performed in Excells 2010 for Microsoft
Windowss. The dissolution proﬁles were compared using the
f2-method as recommended by the United States Pharmacopoeia
[18–20]. The percentages of dissolution at each time point wereTable 1 Counterfeit samples of Viagras with their galenic form an
Sample no. Product name Galenic form
1 – Tablets
2 – Soft tablets
3 Viagra Tablets
4 Suhagra Filmcoated tab
5 – Tablets
6 Filagra Tablets
7 Kamagra Chewing table
8 – Filmcoated tab
9 – Filmcoated tab
10 – Filmcoated tab
11 – Soft tablets
12 Lady-Era Tablets
13 Sildigra Soft tablets
14 Afrika black ant rouge Capsules
15 Hercules capsules Capsules
16 Vajra Capsules
17 Hard Ten Days Capsules
18 Kamagra Oral gelcompared using the Cochran test, which is an adapted t-test that
can be used in the case of heteroscedastic data [21].3. Results and discussion
3.1. Quantiﬁcation of the active ingredients
Eighteen counterfeit and imitation samples for both Viagras and
Cialiss were tested for their dissolution. For each sample the
content of sildenaﬁl and tadalaﬁl was determined on one dosage
unit. This was done due to the limited number of dosage units per
sample available.
3.1.1. Sildenaﬁl-containing samples
Table 1 shows the set of 18 samples containing sildenaﬁl used for
the dissolution testing. Based on the packaging, the marks on the
blisters and/or the tablets, all the samples should contain 100 mg
of sildenaﬁl per dosage unit. However, the content determination
on one dosage unit showed that the content varied between 51.57
and 114.33 mg per dosage unit and that 6 samples (samples 1, 3,
13, 14, 15 and 18) did not meet the quality criteria of 95–105% of
the active ingredient as set for pharmaceutical specialities. These
results should be treated with caution since the dosage was
determined on only one dosage unit and following the European
pharmacopoeia criteria for content uniformity, an individual
dosage unit can deviate between 75% and 125% of the dosage
claimed by the manufacturer [15]. This would mean that only two
samples (samples 1, 13) do not meet the quality criterion for
content.
3.1.2. Tadalaﬁl-containing samples
Table 2 shows the 18 counterfeit samples containing tadalaﬁl used
for dissolution testing.
Based on the packaging, the marks on the blisters and/or the
tablets, all samples should contain 20 mg of tadalaﬁl per dosage
unit. However, the content determination on one dosage unit
showed that the content varied between 17.15 and 21.85 mg per
dosage unit and that 9 samples (samples 3–6, 10, 12 and 15–17)d their content determined on 1 dosage unit.
Content (mg/unit) % theoretical content
51.57 51.57
104.85 104.85
87.03 87.03
lets 98.56 98.56
103.79 103.79
99.55 99.55
ts 102.81 102.81
lets 101.63 101.63
lets 96.13 96.13
lets 96.73 96.73
100.05 100.05
97.77 97.77
59.16 59.16
114.33 114.33
94.46 94.46
100.67 100.67
96.16 96.16
92.68 92.68
Table 2 Counterfeit samples of Cialiss with their galenic
form and their content determined on 1 dosage unit.
Sample
no.
Product
name
Galenic
form
Content
(mg/unit)
% theoretical
content
1 – Filmcoated
tablets
21.01 105.05
2 – Tablets 19.12 95.60
3 – Filmcoated
tablets
18.90 94.50
4 Tadora Filmcoated
tablets
18.39 91.95
5 – Soft tablets 18.03 90.15
6 – Chewing
tablets
17.15 85.75
7 – Filmcoated
tablets
19.60 98.00
8 – Filmcoated
tablets
19.01 95.05
9 – Filmcoated
tablets
20.54 102.70
10 Erectaﬁl ST Soft tablets 18.36 91.80
11 – Chewing
tablets
21.08 105.40
12 TADALA Filmcoated
tablets
18.25 91.25
13 – Tablets 21.22 106.10
14 TAZALIS Tablets 20.78 103.90
15 – Filmcoated
tablets
18.86 94.30
16 – Filmcoated
tablets
18.37 91.85
17 – Filmcoated
tablets
21.85 109.25
18 TDFIL Tablets 19.24 96.201
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Fig. 1 (A) Mean dissolution proﬁles of Viagras 100 mg and 12
counterfeited tablets; (B) mean dissolution proﬁles of Viagras 100 mg
and the samples of capsules (samples 14, 15, 16, 17), soft capsules
(sample 13) and oral gel (sample 18).
Dissolution of counterfeit medicines 253did not meet the quality criteria of 95–105% of the active
ingredient as set for pharmaceutical specialities. Again caution is
advised with these results since the quantiﬁcation was performed
on a single dosage unit.3.2. Dissolution tests
3.2.1. Sildenaﬁl-containing samples
Each of the counterfeit/imitation samples as well as a genuine
Viagras sample containing 100 mg sildenaﬁl was tested for dissolu-
tion. These tests were performed in triplicate (three dosage units per
sample), due to the limited amounts of sample units available.
Fig. 1A shows the mean dissolution proﬁles (of three dosage units)
of the 12 counterfeited tablets tested and the genuine product. Fig. 1B
shows the ones obtained for the four capsules, the soft capsules, the
oral gel and the genuine product. The standard errors at each time
point are given in Table 3. The ﬁgures represent the cumulative
percentages of sildenaﬁl liberated from the formulations in function of
time, where 100% dissolution is reached when the complete amount
of sildenaﬁl present in the formulation is liberated. From the proﬁles
it can be concluded that for the genuine product 100% (74.51%)
dissolution is reached at 30 min. This is also the case for samples 1,
5, 6 and 7, but it can be observed that the release from these samples
is slower during the ﬁrst 15 min, compared to the genuine tablets.For seven samples, from which four were tablets (samples 2, 9, 10
and 12), two capsules (samples 16 and 17) and the last oral gel
(sample 18), 100% release was not reached within the duration of the
test (120 min). The oral gel (sample 18) also showed a decreased
dissolution between 30 and 45 min. This was conﬁrmed when
repeating the test with three new samples and is possibly due to
the exhaustion of the solubilising effect of the gel compounds. For the
tablets of sample 3 and the capsules of sample 15, 100% dissolution
was yet achieved at 10 and 15 min, respectively, while for the tablets
of samples 8 and 11 and the capsules of samples 13 and 14, the 100%
release was attained at 120 min.
From the dissolution proﬁles it could be observed that for 14 of
the 18 samples the release of sildenaﬁl from the dosage units was
slower compared to Viagras.
For an objective comparison of the dissolution proﬁles the
f2-values as described by Freitag et al. [18] were calculated. It is
considered that two dissolution proﬁles are equivalent when the
f2-value is between 50 and 100, which means that the proﬁles
show a difference of maximum 10% at each time point.
Table 4 shows the f2-values calculated for each of the 18
counterfeited samples toward the dissolution proﬁle of genuine
Viagras 100 mg. From this table it can be seen that only sample 1
has an f2-value above 50, meaning that the dissolution proﬁle of
this sample can be considered as equivalent to the one of the
genuine product, though it should be kept in mind that this sample
contains only 51% of the labelled dose (100 mg) and therefore
cannot be considered as equivalent to the genuine product. All
other samples have f2-values situated in the range of 7–50, where
samples 3 and 4 have values close to 50. These samples can
therefore be considered as not equivalent to Viagras 100 mg.
Table 3 Standard errors for each time point of the dissolution of Viagras and the 18 counterfeited/imitated samples.
Sample no. Time (min)
0 5 10 15 30 45 60 120
VIAGRA 0.00 13.22 9.29 6.34 4.51 3.29 3.32 2.59
1 0.00 6.46 4.53 1.81 1.79 1.03 0.58 0.38
2 0.00 16.08 17.31 19.89 12.66 7.38 5.37 2.20
3 0.00 10.17 1.83 1.46 2.00 1.69 7.69 2.34
4 0.00 5.05 3.68 1.59 1.72 1.57 1.54 1.05
5 0.00 13.45 15.70 5.10 2.12 0.61 0.81 0.88
6 0.00 150.96 17.14 7.36 2.81 1.24 0.93 1.29
7 0.00 16.04 12.60 8.23 1.87 1.95 1.37 0.53
8 0.00 17.50 19.59 18.06 10.45 5.68 3.29 1.03
9 0.00 7.67 3.56 3.78 9.38 9.46 8.77 5.31
10 0.00 38.11 30.63 31.84 21.65 17.74 15.19 9.27
11 0.00 9.64 8.78 11.61 8.14 5.35 4.55 3.15
12 0.00 10.02 13.07 11.29 6.84 4.67 0.58 3.60
13 0.00 0.00 0.00 173.21 57.32 15.80 6.51 4.67
14 0.00 3.00 4.19 4.42 4.17 3.34 3.35 2.05
15 0.00 29.41 14.38 15.73 13.06 11.07 9.79 8.98
16 0.00 84.65 20.46 15.98 11.87 9.22 8.40 7.09
17 0.00 75.49 28.56 15.80 13.39 15.84 14.33 14.91
18 0.00 84.13 11.22 7.02 18.22 83.74 83.47 3.62
Table 4 f2-Values calculated for the 18 counterfeited samples toward the dissolution proﬁle of Viagra
s 100 mg.
Sample no. f2-Value Sample no. f2-Value Sample no. f2-Value
1 53.07 7 37.41 13 7.36
2 21.31 8 27.38 14 29.90
3 49.44 9 16.23 15 43.73
4 47.24 10 17.38 16 24.08
5 39.18 11 21.80 17 21.94
6 26.95 12 36.51 18 39.05
E. Deconinck et al.254In order to obtain a more thorough comparison of the dissolu-
tion proﬁles, the dissolution at each time point was compared
statistically. Since the F-tests at the different time points showed
that the data were heteroscedastic, an adapted t-test, called the
Cochran test [21], was performed in which the mean dissolution at
each time point of the counterfeited samples was compared to the
value obtained for the genuine product. Table 5 shows the t-values
as calculated for each time point and each counterfeit sample
toward the dissolution of the genuine product. From the results it
can be concluded that only for two samples (samples 1 and 15) the
t-value is smaller than the critical value (2.920) and this at each
time point. This means that based on the Cochran test the
dissolution proﬁles of these two samples are equivalent to the
one of the genuine product, though again sample 1 contains only
51% of the labelled dose and can therefore not be considered as
equivalent with the genuine product. For all other samples
signiﬁcant differences are observed for at least one time point.
For sample 1 both the f2-value and the Cochran test indicate an
equivalence with the dissolution of the genuine product, since the
f2-value is higher than 50 and the Cochran test does not show a
statistically signiﬁcant difference for the different time points in
the proﬁle. For sample 15, however, the f2-value was lower than50 (43.7) while the Cochran test could not detect any difference
between the dissolution values at each time point of the sample
and the genuine product. When examining the dissolution proﬁles
(Fig. 1B) it can be seen that the dissolution of sample 15 is indeed
less equivalent to that of Viagras compared to sample 1.
The standard deviations for sample 15 are much higher than for
sample 1 and the genuine product. To conclude it can be stated
that none of the samples can be considered as equivalent to the
genuine product, since sample 1 contains only 50% of the labelled
dose and the f2-value for sample 15 is lower than 50.3.2.2. Tadalaﬁl-containing samples
As for the samples containing sildenaﬁl, each of the selected
counterfeit/imitation samples as well as a genuine Cialiss sample,
containing 20 mg of tadalaﬁl, was tested for dissolution. Again the
dissolutions were only performed in triplicate.
Fig. 2 shows the mean dissolution proﬁles obtained for the 18
counterfeited/imitation tablets and the genuine product. The
standard errors at each time point are given in Table 6. The
ﬁgures represent the cumulative percentages of tadalaﬁl liberated
from the formulations in function of time, where 100% dissolution
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Fig. 2 Mean dissolution proﬁles of Cialiss 20 mg and 18 counter-
feited tablets.
Table 5 t-Statistics calculated for the Cochran test at each time point for each counterfeited samples of Viagras 100 mg (absolute values
lower than the critical t value (2.920) are indicated in bold).
Sample no. Time (min)
5 10 15 30 45 60 120
1 2.510 2.092 1.947 0.358 1.819 1.817 1.986
2 9.456 9.082 6.007 3.155 2.871 2.776 3.147
3 0.172 1.746 3.348 3.990 4.550 2.448 4.452
4 1.846 2.634 3.535 3.945 4.474 3.890 4.540
5 4.994 2.605 0.394 0.818 1.834 1.778 2.665
6 4.463 4.222 1.216 0.267 0.989 0.749 0.050
7 5.331 3.179 1.132 0.096 0.073 0.981 1.244
8 6.206 5.362 4.337 3.797 3.376 2.802 0.609
9 10.711 13.337 16.059 10.120 6.244 4.008 1.217
10 8.816 8.363 5.840 4.948 3.751 3.161 2.189
11 9.531 10.576 8.909 2.918 1.531 1.036 0.083
12 5.592 2.760 2.123 2.319 2.383 4.807 2.321
13 13.097 18.643 27.252 16.110 9.256 4.318 3.119
14 7.820 6.599 5.577 3.637 1.793 1.170 0.058
15 1.384 0.372 1.138 1.520 1.862 2.072 2.214
16 7.637 5.031 3.262 2.165 1.667 1.340 0.799
17 5.299 5.772 5.995 4.070 2.334 2.172 1.528
18 7.791 10.492 10.459 3.247 1.522 1.314 4.734
Dissolution of counterfeit medicines 255is reached when the complete amount of tadalaﬁl present in the
formulation is liberated. From the proﬁles it can be concluded that
for the genuine product a maximum of 96.54% (71.53%)
dissolution is obtained after 1 h. Only one sample (sample 15)
attains an equivalent percentage dissolution after 1 h. Two other
samples (samples 2 and 4) reach a similar plateau, with the
difference that the plateau is already attained at 45 min. Four
samples (samples 1, 9, 13 and 18) reach a plateau at 60 min, but
lower percentages of dissolution are attained. One sample (sample
16) reaches a dissolution of 100% after 2 h, while for all other
samples no plateau is obtained. For these samples the amount of
tadalaﬁl released is still increasing after 2 h and the percentage
dissolution for these samples at 2 h varies between 20% and 90%.
Visual inspection of the proﬁles also shows that for 11 samples
the release of tadalaﬁl from the formulation is slower than for the
genuine product. For three samples (samples 2, 3 and 4) the release
is faster, while for the remaining samples (samples 9, 10, 15 and
16) a comparable release rate can be observed.
Again for each of the counterfeited/imitated samples the f2-
values were calculated toward the dissolution proﬁle of Cialiss20 mg (Table 7). From these values it can be concluded that for six
samples (samples 3, 4, 9, 15, 16 and 18) an f2-value between 50
and 100 was obtained, showing that they have an equivalent
dissolution proﬁle with the genuine products. For the other
twelve samples, the f2-values are situated in the range between 5
and 45.
As for the sildenaﬁl-containing samples, the Cochran test was
performed for each of the counterfeited/imitated samples toward
the dissolution proﬁle of Cialiss 20 mg. The t-values for each of
the 18 samples are given in Table 8. From the results it can be
concluded that when all time points are compared individually,
only for three samples (samples 4, 9 and 15) no statistically
signiﬁcant differences could be observed for all the time points
compared to Cialiss 20 mg. For all other samples signiﬁcant
differences could be observed for at least one time point.
Three of the six samples (samples 4, 9 and 15) considered
equivalent to Cialiss 20 mg based on the f2-values are also considered
as equivalent based on the Cochran test. For samples 3, 16 and 18 this
is not the case. Samples 16 and 18 show signiﬁcant differences for the
amounts of tadalaﬁl released at 30 and 120 min, respectively. It should
also be mentioned that for these three samples standard deviations of
the dissolution values were much higher than the ones obtained for
samples 4, 9 and 15. For sample 3 the dissolution is signiﬁcantly
different from the one obtained for Cialiss 20 mg from 30 min on.
Sample 3 can be considered as a borderline sample. It shows an f2-
value of 52.25, which is near the limit of 50 and the results of the two
tests performed are not consistent. For this sample it would be advised
to repeat the dissolution testing with more units, possibly resulting in
less variation on the results and a lower f2-value. Due to a lack of
samples, this extra test could not be performed.
Generally it could be concluded that based on the two
statistical tests performed and taken into account that the analysis
was only performed in triplicate, samples 4, 9 and 15 can be
considered as equivalent to Cialiss 20 mg, since the f2-values
were higher than 50 and at no time point a signiﬁcant difference
was detected with the Cochran test. For sample 3 no conclusion
could be formulated.
Table 7 f2-Values calculated for the 18 counterfeited samples toward the dissolution proﬁle of Cialis
s 20 mg.
Sample no. f2-Value Sample no. f2-Value Sample no. f2-Value
1 40.81 7 5.75 13 25.50
2 44.99 8 13.82 14 31.32
3 52.25 9 71.13 15 71.06
4 64.99 10 29.50 16 57.74
5 13.37 11 29.58 17 22.87
6 33.28 12 33.00 18 58.89
Table 6 Standard errors for each time point of the dissolution of Cialiss and the 18 counterfeited/imitated samples.
Sample no. Time (min)
0 5 10 15 30 45 60 120
CIALIS 0.00 33.37 24.20 12.77 2.30 2.33 1.53 1.54
1 0.00 40.94 29.35 18.16 11.23 7.79 5.84 5.08
2 0.00 2.48 1.99 0.97 1.69 3.10 1.14 0.71
3 0.00 13.60 7.92 5.18 2.71 0.77 1.80 0.70
4 0.00 25.45 8.22 5.92 1.55 1.34 1.22 0.88
5 0.00 6.27 12.67 9.03 2.52 1.92 1.03 1.09
6 0.00 3.42 3.36 4.59 2.46 1.76 1.83 2.57
7 0.00 20.31 15.48 23.20 26.43 23.88 26.94 19.72
8 0.00 39.74 43.78 42.05 38.73 31.09 28.86 20.77
9 0.00 11.24 6.50 0.92 0.77 2.32 1.79 1.85
10 0.00 5.97 6.76 3.62 2.92 2.62 1.21 0.75
11 0.00 10.63 7.34 6.83 5.03 4.68 3.33 4.41
12 0.00 15.67 0.20 1.78 3.65 5.19 6.47 6.19
13 0.00 29.56 26.13 19.89 18.76 16.52 15.88 13.43
14 0.00 9.51 9.20 9.83 7.47 5.84 5.51 3.73
15 0.00 23.42 7.17 2.99 1.91 1.94 1.43 1.72
16 0.00 11.61 3.67 2.39 1.43 2.52 1.87 1.59
17 0.00 7.40 3.51 7.77 1.43 3.12 3.07 1.97
18 0.00 6.66 5.04 4.88 3.71 3.68 3.80 2.21
E. Deconinck et al.2564. Conclusions
In general it can be concluded that for the counterfeit samples high
variations of the dissolution values (Tables 3 and 6) were observed
and this both between the dosage units of one sample as between
the different counterfeited samples. Moreover, it was observed that
for the majority of the samples (sildenaﬁl and tadalaﬁl), higher
standard deviations were found at time points of 5, 10 and 15 min
compared to the deviations found for the genuine products. The
other time points showed lower standard deviations, which is
characteristic for dissolution proﬁles reaching a plateau. The
higher variations at the beginning of the dissolution proﬁles might
be due to a difference in disintegration between the samples,
but also between the dosage units of one sample. This can
inherently be related to the quality of the counterfeit/imitation
products. Possible factors responsible for the lower quality of the
tablets are the variable particle size of the active ingredients, the
use of less qualitative primary substances, the use of different
excipients or the correct excipients in different amounts, improper
transport and storage conditions, and differences in productionprocess as to high compression for tablet production or low
moisture content.
The results also showed that for the sildenaﬁl-containing
samples no sample and for the tadalaﬁl-containing samples only
three samples (16.7%) could be considered as having an equivalent
in vitro dissolution proﬁle with the genuine product. Taking into
account that in vitro dissolution is an indicator for bioequivalence,
this indicates that even when in a counterfeit product the correct
active ingredient and dosage is found, the product can still be
considered as a risk for public health. If the trend observed for
PDE-5 inhibitors could be extended to life-saving medicines like
antibiotics, anti-viral and anti-parasitic products, this can lead to
ineffective treatment, development of resistance, and a loss of faith
in health care, regulating authorities and the pharmaceutical
industry.
Finally, it can also be stated that for the comparison of
dissolution proﬁles, especially when not enough dosage units are
available, the combination of both the f2-methods as the compar-
ison of the dissolution at each time point can be very valuable,
leading to objective conclusions in line with visual observations.
Table 8 t-Statistics calculated for the Cochran test at each time point for each counterfeited samples of Cialiss 20 mg (absolute values
lower than the critical t value (2.920) are indicated in bold).
Sample no. Time (min)
5 10 15 30 45 60 120
1 0.911 1.054 1.953 3.395 3.916 5.484 5.764
2 3.958 1.176 0.314 0.379 0.384 0.599 0.163
3 1.263 0.555 1.619 6.151 6.040 6.235 6.696
4 0.844 0.671 0.562 1.044 2.233 0.799 1.249
5 3.637 5.217 9.380 45.816 42.865 64.939 60.965
6 0.060 2.230 4.601 17.829 15.057 16.525 10.964
7 5.085 6.984 13.067 60.511 46.769 43.217 30.811
8 2.633 4.456 7.062 9.579 9.178 8.356 7.466
9 0.331 0.681 0.486 2.692 0.876 1.551 2.093
10 1.185 2.931 5.520 19.715 15.072 23.129 17.615
11 0.162 2.406 4.770 14.461 12.274 16.497 11.830
12 0.525 2.266 4.740 15.475 8.703 7.313 4.359
13 2.209 2.834 4.266 5.382 5.178 5.315 6.181
14 1.815 2.638 4.423 9.054 8.037 8.170 9.180
15 0.852 0.389 0.455 0.872 0.930 1.131 0.499
16 0.917 1.034 1.693 4.076 0.661 1.655 2.748
17 3.224 4.344 7.420 30.752 18.489 18.824 12.545
18 0.509 0.712 1.659 3.854 1.213 1.746 2.950
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Supplementary data associated with this article can be found in the
online version at http://dx.doi.org/10.1016/j.jpha.2014.03.002.References
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